Granisetron reduces post-operative vomiting in children: a dose-ranging study

Area of Science:

• Anesthesiology
• Pharmacology
• Pediatric Surgery

Background:

• Post-operative vomiting (POV) is a common complication in pediatric surgery.
• 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, like granisetron, are used for antiemesis.
• Determining the optimal dose is crucial for efficacy and safety.

Purpose of the Study:

• To identify the minimum effective dose of granisetron for preventing POV in children.
• To compare the efficacy of different granisetron doses against placebo.
• To evaluate the safety profile of granisetron in pediatric surgical patients.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 120 pediatric patients (ASA I, 4-10 years).
• Patients received placebo or granisetron (20, 40, or 100 micrograms kg-1) intravenously post-anesthesia.
• Complete response was defined as no emesis and no need for rescue antiemetics within 24 hours.

Main Results:

• Complete response rates were 57% (placebo), 67% (20 mcg/kg), 90% (40 mcg/kg), and 90% (100 mcg/kg).
• Granisetron at 40 mcg/kg and 100 mcg/kg showed significantly higher efficacy than placebo (P < 0.05).
• No significant difference in efficacy was observed between 40 mcg/kg and 100 mcg/kg doses. No adverse events were noted.

Conclusions:

• Granisetron 40 micrograms kg-1 is the minimum effective dose for preventing emesis in pediatric surgery.
• Higher doses of granisetron (up to 100 micrograms kg-1) do not provide additional antiemetic benefits.
• This finding supports optimizing granisetron dosage for effective post-operative vomiting prevention in children.